Lord, Abbett & Co
SLNO

Lord, Abbett & Co’s Soleno Therapeutics SLNO Stock Holding History

Lord, Abbett & Co’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-60,744
Closed -$4.11M – 596
2025
Q3 		$4.11M Sell
60,744
-75,764
-56% -$5.62M 0.01% 479
2025
Q2 		$11.4M Buy
136,508
+81,447
+148% +$6.1M 0.04% 365
2025
Q1 		$3.93M Buy
+55,061
New +$2.68M 0.01% 478

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lord, Abbett & Co's SLNO Position: Q4 2025 in Review

Lord, Abbett & Co sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 60,744 shares — an estimated $4.11M sold.

Lord, Abbett & Co first reported a position in SLNO in Q1 2025 and held it in 3 quarters. The position peaked at $11.4M in Q2 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • Lord, Abbett & Co reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 60,744 Soleno Therapeutics shares in Q4 2025, an estimated $4.11M.
  • Lord, Abbett & Co first reported a position in Soleno Therapeutics in Q1 2025 and held it in 3 quarters.
  • Lord, Abbett & Co's Soleno Therapeutics position peaked at $11.4M in Q2 2025.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Lord, Abbett & Co's 13F filing for Q4 2025, filed 13 Feb 2026.